Previous Article | Next Article ![]()
Journal of Virology, September 2000, p. 8077-8084, Vol. 74, No. 17
Laboratory of Cellular and Molecular
Biophysics, National Institute of Child Health and Human
Development, National Institutes of Health, Bethesda, Maryland 20892
Received 21 September 2000/Accepted 8 June 2000
Progression of human immunodeficiency virus (HIV) disease is
associated with massive death of CD4+ T cells along with
death and/or dysfunction of CD8+ T cells. In vivo, both HIV
infection per se and host factors may contribute to the death and/or
dysfunction of CD4+ and CD8+ T cells.
Progression of HIV disease is often characterized by a switch from R5
to X4 HIV type 1 (HIV-1) variants. In human lymphoid tissues ex vivo,
it was shown that HIV infection is sufficient for CD4+
T-cell depletion. Here we address the question of whether infection of
human lymphoid tissue ex vivo with prototypic R5 or X4 HIV variants
also depletes or impairs CD8+ T cells. We report that
whereas productive infection of lymphoid tissue ex vivo with R5 and X4
HIV-1 isolates induced apoptosis in CD4+ T cells,
neither viral isolate induced apoptosis in CD8+ T
cells. Moreover, in both infected and control tissues we found similar
numbers of CD8+ T cells and similar production of cytokines
by these cells in response to phorbol myristate acetate or
anti-CD3-anti-CD28 stimulation. Thus, whereas HIV-1 infection per se
in human lymphoid tissue is sufficient to trigger apoptosis in
CD4+ T cells, the death of CD8+ T cells
apparently requires additional factors.
AIDS is a multifactorial disease
which starts with human immunodeficiency virus (HIV) infection of
CD4+ cells and eventually leads to deterioration of
lymphoid tissue (12). This is accompanied by massive death
of CD4+ T cells along with death and/or dysfunction of
various CD4 In vivo, both HIV infection per se and host factors may contribute to
the death and/or dysfunction of CD4+ and CD8+ T
cells in lymphoid tissue (11, 47). From our experiments with
ex vivo human lymphoid tissue, we know that productive HIV infection
alone is sufficient to cause CD4+ T-cell depletion
(20, 49, 59). Whereas productive R5 infection of lymphoid
tissue ex vivo depletes the small fraction of CD4+ T cells
(20, 49) that express CCR5 (28), X4 infection
severely depletes the entire CD4+ T-cell population
(20, 28, 49). Here, we address the question of whether
infection of human lymphoid tissue ex vivo with R5 or X4 HIV variants
also depletes or impairs CD8+ T cells. We compared the
frequency of apoptosis and the absolute number of
CD4+ and CD8+ T lymphocytes in human lymphoid
tissue infected ex vivo with prototypic X4 and R5 isolates. We found
that whereas HIV type 1 (HIV-1) infection per se is sufficient to
induce apoptosis of tissue CD4+ T cells, it neither
triggers apoptosis of CD8+ T cells nor decreases
the responsiveness of these cells to activators.
Viruses.
Prototypic R5 HIV-1 isolate SF162 and X4 isolate
LAV.04 were obtained through the AIDS Research and Reference Reagent Program.
HIV infection of human lymphoid tissue ex vivo.
Human
tonsils removed during routine tonsillectomy were received within
several hours of excision. The tonsils were washed thoroughly with
medium containing antibiotics and then sectioned into 2 to 3-mm blocks
with an average weight of 3 mg. To compare the absolute number of
lymphocytes in infected and control tissues, blocks were matched by
size and weight. Tissue blocks were placed on top of collagen sponge
gels in the culture medium at the air-liquid interface and infected the
next day as described earlier (20, 21). The spontaneous loss
of cells from the tissue blocks occurs in the first 36 h after
dissection. Therefore, in several experiments infections were delayed
for 36 h. In a typical experiment, 3 to 5 µl of clarified
virus-containing medium (approximately 300 50% T-cell infective
doses/block) was applied to the top of each tissue block. At this
concentration both viruses replicate to approximately the same level
(20). Productive HIV infection was assessed by measuring p24
in the culture medium using an HIV-1 p24 antigen enzyme-linked
immunosorbent (ELISA) (AIDS Vaccine Program, National Cancer Institute,
Frederick, Md.): specifically, the concentration of p24 accumulated in
4 ml of culture medium bathing nine tissue blocks during the 3 days
between the successive medium changes was used as a measure of virus replication.
Flow cytometry.
Flow cytometry was performed on cells
mechanically isolated from control and infected tissue blocks
(21). Lymphocytes were first identified according to their
light-scattering properties and then analyzed for expression of
lymphocyte markers. More than 95% of cells in the lymphocytic gate
express lymphocytic markers (21) and exclude propidium
iodide. Depletion of CD4+ T cells was assessed as described
earlier (21). For determination of the CD4+ and
CD8+ T cells, cells were stained for surface markers using
anti-CD3-TriColor, anti-CD4-phycoerythrin (PE), and
anti-CD8-fluorescein isothiocyanate (FITC) antibodies (Caltag,
Burlingame, Calif.). To enumerate cells in tissue blocks, we used
Trucount tubes (Becton Dickinson, San Jose, Calif.) containing a known
number of fluorescent beads. The absolute number of cells in the sample
can be determined by normalizing to the number of acquired beads. To
evaluate proliferation, cells were first stained with
anti-CD3-TriColor, anti-CD8-FITC, and anti-CD4 allophycocyanin (APC)
antibodies, washed, fixed and permeabilized with Cytofix-Cytoperm
(PharMingen, San Diego, Calif.) according to the manufacturer's
protocol, and then stained with anti-Ki67-PE (PharMingen) or with
control isotype antibodies. To evaluate activation, cells were stained
with anti-CD8-FITC, anti-CD27-PE, and anti-CD28-TriColor antibodies and
with APC-labeled antibodies against either HLA-DR or CD38 and then
fixed. Cells were acquired on a FACSCalibur using CellQuest software
for both acquisition and analysis.
Apoptosis.
Cells were stained for one of the following cell
surface antigen combinations: CD3-TriColor, CD8-FITC, and CD4-APC
(Caltag); or CD4-TriColor (Caltag), CCR5-APC, and CXCR4-APC
(PharMingen). After washing, cells were fixed and permeabilized using
Cytofix-Cytoperm (PharMingen) according to the manufacturer's
instructions and stained for the mitochondrial antigen 7A6 using
monoclonal antibody Apo 2.7-PE (Immunotech, Marseille, France). In
another apoptosis assay, the activity of caspase 3 was measured
by the fluorogenic substrate PhiPhiLux (OncoImmunin, Inc., College
Park, Md.). Cells were isolated from tissue blocks, thoroughly washed,
incubated with the substrate solution, and then stained for cell
surface antigens. Cells were analyzed by flow cytometry. For a positive control for apoptosis, peripheral blood mononuclear cells
(PBMCs) were incubated overnight with 3 µM staurosporine (Sigma, St.
Louis, Mo.). The number of 7A6+ cells increased from 5% to
more than 60%.
Cytokine production in response to stimulation.
Lymphocytes
were mechanically isolated from control and infected tissue blocks 8 to
10 days postinfection. Cells were counted and stimulated either with
phorbol myristate acetate (PMA) plus ionomycin or with anti-CD3 and
anti-CD28 antibodies. For direct protein kinase C (PKC) stimulation,
106 cells/ml were incubated with PMA (50 ng/ml) and
ionomycin (500 ng/ml Sigma) in the presence of brefeldin A (GolgiPlug;
Pharmingen) for 4 h. Cells were washed, stained for cell surface
antigens CD8-FITC and CD3-TriColor (Caltag), and then fixed and
permeabilized with Cytofix-Cytoperm according to the manufacturer's
instructions. Permeabilized cells were stained with either of three
cytokine-specific monoclonal antibodies (interleukin-2 [IL-2]-PE,
gamma interferon [IFN- Experimental analysis.
Data obtained with tissue from one
donor constitute the results of one experiment. Both viral replication
and the proportion of cells in various leukocyte subsets varied from
tissue to tissue (21). To compare results obtained in
different experiments, we normalized the data for such variation: for
each experiment we compared infected and control tissues in replicates
of at least three histocultures of nine tissue blocks each, obtained
from an individual donor. To average the results of different
experiments and analyze them statistically, we normalized the data as
percentage of the control.
We compared apoptosis in CD4+ and
CD8+ T lymphocytes in human lymphoid tissue infected ex
vivo with prototypic X4 isolate LAV.04 or prototypic R5 isolate SF162.
Apoptosis was evaluated by flow cytometry using antibodies against the
mitochondrial membrane antigen 7A6, which is exposed at early stages of
apoptosis (36, 41), before cells lose their normal
optical characteristics, surface markers, and become permeable to
propidium iodide. Therefore, we were able to confine our analysis of
apoptotic cells to the lymphocytic gate as defined by a light
scatter plot in which cells are readily identifiable.
Both isolates productively infected tissue blocks with the typical
kinetics described earlier (20, 49) and presented in Fig.
1. Viral replication, as evaluated by p24
concentration in culture medium, was detectable typically between days
6 and 9 postinfection and continued to increase until days 12 to 13 postinfection. At that time point in LAV.04-infected cultures,
CD4+ T lymphocytes were depleted by about 80%. Among the
remaining CD4+ T cells, apoptosis, as defined by
expression of 7A6 mitochondrial antigen, was fourfold higher than in
matched uninfected controls (Fig. 2a),
which on average was 6 ± 2% (mean ± standard error of the
mean [SEM]; n = 6). (When data for all uninfected
control tissues were pooled, the average proportion of
apoptotic cells on days 11 to 13 in culture was 5% ± 1%
[n = 11].) An increase in CD4+ T-cell
apoptosis in LAV.04-infected tissues was also revealed in
experiments with PhiPhiLux, which measures caspase 3 protease activity
(data not shown). In contrast, the frequency of apoptosis among
CD8+ T cells from the same LAV.04-infected tissues was
similar to that from uninfected controls (Fig. 2a). Apoptosis in both
CD4+ and CD8+ T cells from SF162-infected
tissue blocks was also similar to that from uninfected controls (Fig.
2a).
0022-538X/00/$04.00+0
Human Immunodeficiency Virus Type 1 Induces Apoptosis in
CD4+ but Not in CD8+ T Cells in Ex
Vivo-Infected Human Lymphoid Tissue
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
cells thought not to be infectible by the
virus (7, 16, 25, 56). Among CD4
cells,
CD8+ T cells are thought to play a major role in HIV
disease control as a source of soluble factors (8, 38) and
as cytotoxic T lymphocytes (CTLs) (63). Failure of these
cells to contain HIV infection is thought to be a major cause of HIV
disease progression (63). Early stages of HIV disease, when
CCR5-tropic (R5) HIV variants dominate (10, 54, 55), are
characterized by expansion (14) and accelerated turnover
(53, 65) of CD8+ T cells. At later stages of HIV
disease, when variants that use either CXCR4 alone (X4) or both CXCR4
and CCR5 (R5/X4) often become dominant (10, 54), the
absolute number of CD8+ T cells gradually decreases
(14, 39). The emergence of X4 or R5X4 variants often
coincides with a rapid decline in T-cell counts and the development of
AIDS (55, 60).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
]-PE, and tumor necrosis factor alpha
[TNF-
]-PE [Caltag]) and relevant isotype controls. To stimulate
CD8+ T cells via the T-cell receptor complex, 4 × 106 cells/ml were cultured in anti-CD3 antibody-coated
wells (UCHT1; 10 µg/ml; PharMingen) in the presence of soluble
anti-CD28 antibody (CD28.2; 2 µg/ml; PharMingen). Cells were washed,
permeabilized, and stained for cytokine production as described above.
Preliminary experiments with noninfected tissues showed that optimal
stimulation was achieved at 40 h. Therefore, we chose this time
point to compare stimulation of CD8+ T cells in control and
HIV-infected tissues.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (15K):
[in a new window]
FIG. 1.
Replication of HIV-1 in tissues infected with X4 and R5
isolates. Human tonsils removed during routine tonsillectomy were
dissected into 2 to 3-mm blocks inoculated with virus-containing medium
and cultured as described in Materials and Methods. Productive HIV
infection was assessed by measuring p24 released into the culture
medium.


View larger version (48K):
[in a new window]
FIG. 2.
Apoptosis of T lymphocytes in tissues
infected with X4 and R5 HIV-1 isolates. Lymphocytes mechanically
isolated from control and ex vivo-infected tissues were stained for
CD3, CD4, CD8, and the apoptosis-reporting mitochondrial
antigen 7A6 and then analyzed by flow cytometry. (a) Apoptosis in
CD4+ and CD8+ T cells from control and
HIV-infected tissues (mean + SEM [n = 6]). Note
the significant increase in the number of apoptotic
CD4+ T cells remaining in the LAV.04 (X4)-infected but not
SF162 (R5)-infected tissue, while there is no increase in
apoptosis of CD8+ T cells. (b) Apoptosis in
CD4+ and CD8+ T cells isolated at different
time point postinfection (mean + SEM [n = 3]).
In control uninfected tissues, the proportion of apoptotic
CD4+ and CD8+ T cells was between 5 and
7% and 3 and 5%, respectively. Note the increase in apoptosis
in CD4+ but not CD8+ T-cell subset. (c)
Apoptosis in CXCR4+ and CCR5+ subsets of
CD4+ T cells isolated from LAV.04- and SF162-infected
tissues on day 12 postinfection (mean + SEM [n = 3]). Note the selective increase in the number of
apoptotic CCR5+ CD4+ T cells in tissues
infected with the R5 HIV isolate.
To follow its kinetics, we evaluated apoptosis in CD4+ and CD8+ T cells from LAV.04-infected tissues at different time points after infection. Apoptosis in uninfected tissues remained low and varied between 5 and 7% for CD4+ T cells and between 4 and 5% for CD8+ T cells (n = 3). LAV.04 infection increased apoptosis in CD4+ T cells (Fig. 2b). The increase of apoptosis became significant on day 6 postinfection (P = 0.016, n = 4), and the difference between control and infected tissue continued to increase thereafter. At none of the time points was apoptosis significantly elevated in CD8+ T-cell subset (P = 0.84 on day 6 and P = 0.53 on day 12) (Fig. 2b).
Since analysis of general CD4+ T-cell population in
SF162-infected tissues revealed no apoptosis, we analyzed
whether R5 and X4 HIV variants induced apoptosis differently in
CD4+ T cells expressing viral coreceptors CCR5 or CXCR4 on
their surface. More than 80% of CD4+ T lymphocytes in
cultured human lymphoid tissue express CXCR4 but not CCR5, and less
than 10% express CCR5 but not CXCR4 (28). LAV.04 increased
apoptosis almost sixfold in both CXCR4+
CCR5
and CXCR4
CCR5+ subsets of
CD4+ T cells (Fig. 2c). In SF162-infected tissues,
apoptosis was increased more than fourfold in the
CXCR4
CCR5+ subset selectively but did not
change at all in CXCR4+ CCR5
subset of
CD4+ T cells (Fig. 2c).
Apoptosis measurements represent a snapshot, which does not account for
cells that had already undergone apoptosis and had disintegrated. Therefore, we measured the cumulative effect of apoptosis by enumerating CD4+ and CD8+
T cells over the course of infection. On day 0, six control uninfected tissues from different donors contained on average 41,900 ± 7,200 CD4+ T cells and 7,500 ± 1,400 CD8+ T
cells per mg. The number of T cells in these control blocks decreased
over the next 24 h and then stabilized (Fig.
3a and b). On average, the numbers of
CD4+ T cells on days 1 and 13 were similar (P = 0.08). The same was true for CD8+ T cells
(P = 0.47). As was shown earlier and confirmed here, CD4+ T cells in the same tissue blocks were depleted by
almost 80% by days 11 to 13 of LAV.04 infection compared with matched
uninfected control (Fig. 3c). In contrast to CD4+ T cells,
there was no significant difference (P = 0.07, n = 13) in CD8+ T-cell counts between LAV.04-infected and
matched uninfected controls (Fig. 3c). In the case of SF162-infected
tissues, there was mild but significant (P = 0.02)
depletion of CD4+ T cells, whereas depletion of
CD8+ T cells was not significant (P = 0.75)
(Fig. 3c). To determine whether the number of CD8+ T cells
was conserved over the entire 13-day period of experimental infection,
we compared the absolute numbers of CD4+ and
CD8+ T cells in infected and control tissues at different
time points postinfection (Fig. 3d). Whereas the number of
CD4+ T cells in LAV.04-infected tissue blocks declined
starting from about day 6 postinfection, the numbers of
CD8+ T cells remained similar to those in uninfected
controls at all time points (P > 0.06).
|
To ascertain that spontaneous loss of T cells on the first day of culture does not obscure depletion of T cells in HIV-infected tissues, we delayed HIV infection for 36 h, or until the tissue cellularity stabilizes (Fig. 3a and b). This procedure did not change the severe depletion of CD4+ T cells and conservation of CD8+ T cells. In a typical experiment, there were 590 CD4+ T cells/mg in LAV.04-infected tissue and 9,500 CD4+ T cells/mg in the uninfected control, whereas for CD8+ T cells these numbers were 1,600 and 1,400 cells/mg in LAV.04-infected and control tissues, respectively.
To assess cell turnover in ex vivo human lymphoid tissue, we evaluated T-cell proliferation using Ki67. Ki67 is expressed in cycling cells (19) and is considered to be an adequate marker of cell proliferation (5, 19). To verify that Ki67 was evaluated properly, we used a B-cell lymphoma as a positive control. Ki67 was expressed in approximately 75% of these cells, a level of expression similar to that described for lymphoma cell lines (6). Although approximately 10% of CD4+ and 25% of CD8+ T cells expressed Ki67 in tonsillar tissues a few hours after tonsillectomy, proliferation dropped fivefold in the first 24 h of culture, and at the time of infection (36 h posttonsillectomy), only 0.7% ± 0.1% of CD8+ and 0.6% ± 0.1% of CD4+ T cells expressed Ki67 (n = 6). Cell proliferation remained low throughout the experiment. In tissues from three donors, on average 0.8% ± 0.8% and 0.8% ± 0.4% of CD8+ T cells and CD4+ T cells, respectively, were Ki67+ at day 2 postinfection; these numbers were even lower at day 4 (less than 0.25%), and no Ki67+ T lymphocytes were detected on day 7 of culture irrespective of LAV.04 infection.
Also, the level of activation was low in human tonsillar tissue:
four-color flow cytometry revealed that at day 0, 1 to 2% of
CD8+ T cells were of HLA-DR+ CD27
CD28
or CD38+ CD27
CD28
phenotype. On day 5 or 8 postinfection, these cells
constitute less than 1% of CD8+ T cells irrespective of
LAV.04 infection. Thus, in the absence of significant activation,
replenishment, and apoptosis, the numbers of CD8+ T
cells in both HIV-infected and control tissues are conserved.
The question arising from these results is whether HIV tissue infection
ex vivo renders CD8+ T cells dysfunctional. We evaluated
the ability of these cells to produce cytokines in response to the PKC
activator PMA. When T cells were stimulated with PMA-ionomycin, there
was no significant difference (P > 0.5, n = 3) in
cytokine production by CD8+ T cells isolated on day 8 postinfection from LAV.04-infected and matched uninfected control
tissue (Fig. 4a). To test whether HIV
infection impaired the early T-cell receptor signaling events, we
stimulated T cells with anti-CD3 and anti-CD28 antibodies. As shown in
Fig. 4b, there was no significant difference (P > 0.5, n = 3) between the numbers of IL-2-, TNF-
- and
IFN-
-producing CD8+ T cells isolated on day 8 from
LAV.04-infected and matched control tissues. Similar results were
obtained when CD8+ T cells were isolated on day 10 postinfection.
|
| |
DISCUSSION |
|---|
|
|
|---|
HIV-1 infection causes profound changes in the cells constituting the human immune system. In particular, CD4+ T lymphocytes are progressively depleted during the course of infection (12). In contrast, the number of CD8+ T cells in HIV-infected patients is initially increased but often declines at late stages of HIV disease (14, 35, 39). The mechanism responsible for the increased death of CD4+ and CD8+ T cells in HIV-infected human lymphoid tissue is not known. In vivo, the death of T cells is normally balanced by their replenishment (reviewed in reference 18). HIV or simian immunodeficiency virus (SIV) infection disturbs this balance (44, 53). Although the data on both CD4+ and CD8+ T-cell turnover are controversial (15, 33, 46, 51, 65, 66), it is believed that at late stages of HIV/SIV disease the immune system fails to keep pace with cell death (31). Many host factors (e.g., chronic immune activation [9, 12]) modulate HIV-triggered T-cell death and replenishment in lymphoid tissue, where the critical events in HIV disease occur in vivo. On the other hand, it was reported that in vitro CD8+ T-cell death can be caused in PBMCs by HIV infection per se (32).
Apoptosis was implicated as a major mechanism for the death of both
CD4+ and CD8+ T cells in HIV-infected patients
(42, 43, 52; reviewed in reference
27). Here, we tested whether this mechanism also applies to isolated tissue blocks infected with HIV-1 ex vivo. We found
that (i) R5 HIV-1 productive infection induces apoptosis selectively in the CCR5+ subset of CD4+ T
cells, whereas X4 HIV-1 infection induces apoptosis in both CXCR4+ CD4+ and CXCR4
CD4+ T cells; (ii) neither of these isolates induces
apoptosis in tissue CD8+ T cells, and their number
remained similar to those in uninfected controls; (iii) cytokine
production in response to direct PKC or to T-cell receptor stimulation
is similar in CD8+ T cells from HIV-infected and control
tissues. Thus, in lymphoid tissue, HIV productive infection per se is
sufficient for the death of CD4+ but not CD8+ T cells.
The system of human tonsillar tissue ex vivo has been used to study various aspects of HIV pathogenesis (20, 22, 24, 28, 40). This system is different from thymus organ cultures, where 90% of cells undergo gradual apoptosis in 12 days of culture (2). Tonsillar histocultures lose approximately 60% of cells in the first day (probably as a combined result of tissue cutting and background apoptosis), but starting from the next day tissue cellularity stabilizes and the subsequent cell loss is negligible unless the tissue is infected with HIV-1. There is no statistical difference between the number of either CD4+ or CD8+ T lymphocytes in uninfected tissue at any day of culture starting from day 1.
Human lymphoid tissue ex vivo supports replication of different HIV variants and does not require exogenous stimulation (20, 21). In this regard this system is different from isolated PBMCs. One can speculate that tissue blocks do not require exogenous stimulation because lymphocytes in tonsils are already in an activated state since tonsils have been removed from the patients due to their size and probably were infected by bacteria. However, noninflamed lymph nodes (21), spleen (49), and thymus (2, 50) support ex vivo HIV-1 replication also without exogenous stimulation. Moreover, activation seems not to be an absolute condition for a CD4+ T cell to be productively infected in lymphoid tissue either in vivo (69) or ex vivo (23). These results do not necessarily contradict the common notion that it is difficult to infect resting T cells, since the above-mentioned cells may have been in activated state at the time of infection. We think that the endogenous cytokine network together with a preserved system of cell-cell interactions rather than inflammation-related activation make human tonsillar tissue sufficient to support productive HIV-1 infection both in vivo and ex vivo.
In our present work we took advantage of the fact that unlike in vivo, in ex vivo-infected tissues there is no evidence of rapid T-cell turnover, as evaluated by Ki67 expression. Also, in ex vivo-infected human lymphoid tissues the numbers of cells exhibiting phenotypes typical for activated cells, including those commonly associated with CTLs (3, 4, 17, 34), are very low. In this regard, our ex vivo system appears to be different from the situation in vivo (11, 17, 47, 63). Nevertheless, this difference allowed us to evaluate the contribution of HIV infection per se to the death of CD4+ and CD8+ T cells in lymphoid tissue.
As shown earlier (20, 49) and confirmed here, there is
severe depletion of CD4+ T cells in ex vivo lymphoid
tissues productively infected by X4 isolates, whereas R5 isolates
deplete CD4+ T cells only mildly. To address the mechanism
of this depletion, we evaluated apoptosis in control and
infected tissues by measuring expression of the mitochondrial antigen
7A6 (36, 41) and caspase 3 protease activity. The frequency
of apoptotic cells in uninfected control tissue remains
generally low, with a median (5%) almost equal to that reported for
fresh tonsillar tissue (4%) (52). We demonstrated a
significant increase in CD4+ T-cell apoptosis in
lymphoid tissues infected ex vivo by the prototypic X4 isolate LAV.04
but not by the prototypic R5 isolate SF162. This indicates that
depletion of CD4+ T cells by X4 isolates is the result of
cell death rather than their migration out of the tissue. In contrast
to the X4 isolate, productive R5 infection increased apoptosis
selectively in the CCR5+ CXCR4
subset of
CD4+ T cells. Since CCR5+ CXCR4
cells constitute less than 10% of the total CD4+ T-cell
population (28), the increased apoptosis in this
subset does not significantly alter the overall number of
apoptotic CD4+ T cells. Thus, the R5 variant
induces apoptosis in a coreceptor-dependent manner, whereas X4
induces apoptosis irrespective of coreceptor expression. We do
not know whether the increased frequency of apoptosis among
CXCR4
cells in X4-infected tissues represents a bystander
apoptotic death or is a result of direct infection of these
cells, which may express CXCR4 below the threshold of detection but at
a level that is sufficient for infection. Whatever the mechanism of the differential apoptosis in CCR5+ and
CXCR4+ subsets of tissue CD4+ T cells, it
accounts for the differential depletion of these cells by R5 and X4
HIV-1 isolates described earlier (28).
The difference in the ability of R5 and X4 isolates to trigger apoptosis is additional evidence that the emergence of X4 viruses may be sufficient for massive CD4+ T-cell depletion and progression to AIDS (10, 13, 37, 54, 60). Our results with isolated lymphoid tissue indicate that productive viral infection is sufficient to trigger apoptosis and consequent cell death in cognate CD4+ T-cell targets.
In sharp contrast to the effect of HIV infection on CD4+ T cells, neither X4 nor R5 infection induced apoptosis or significantly depleted CD8+ T cells in ex vivo tissue. Also, the level of proliferation of CD8+ T cells was low, as demonstrated by Ki67 measurements. Therefore, we conclude that in ex vivo tissues there is no significant turnover of CD8+ T cells. When the absolute numbers of T cells were repeatedly measured in the course of 13 days of infection, CD4+ T-cell counts started to drop on day 6 postinfection whereas CD8+ T-cell counts even slightly increased at the end of experiment. However, based on our present data this increase in the number of CD8+ T cells is not statistically significant. If proven, such an increase may reflect the observed but statistically not significant low level of proliferation unbalanced by apoptosis. Nevertheless, our data demonstrate that the numbers of CD8+ T cells is conserved in this system in spite of HIV infection.
In HIV-infected individuals, peripheral CD8+ T cells were
reported to be dysfunctional (4, 30, 62). Here, we asked
whether CD8+ T cells in HIV-infected tissue blocks produce
IL-2, TNF-
, and IFN-
upon PMA stimulation differently than do
CD8+ T cells from matched uninfected controls. In neither
case we did find any difference in this regard between CD8+
T cells isolated from HIV-infected and matched control tissue blocks.
Stimulation of CD8+ T cells with PMA bypasses the early
signaling events and affects PKC directly. To assess whether
CD8+ T cells from infected culture responded to
physiological stimuli, we treated them with anti-CD3 and anti-CD28
antibodies that stimulate T cells through the T-cell receptors. This
assay revealed no difference between CD8+ T cells from
infected tissue and uninfected control either on day 8 when
CD4+ T cells become apoptotic and die or at later
days when the depletion of CD4+ T cells becomes severe.
Thus, in human lymphoid tissue, ex vivo HIV infection neither affects
CD8+ T-cell responsiveness to stimulation nor induces apoptosis.
In this regard, the fate of CD8+ T cells in HIV-infected human lymphoid tissue ex vivo is different from what was reported for CD8+ T cells in vivo (16, 45, 52). In particular, increased CD8+ T-cell apoptosis was found in tonsils from HIV-infected individuals (52). The discrepancy between the increased level of CD8+ T-cell apoptosis in HIV-infected lymphoid tissue in vivo and the lack of such an increase in ex vivo-infected tissues may be related to the possible difference in the level of Tat, Nef, Vpr, or other factors that were implicated in apoptosis (57, 58, 64, 67) in various experimental settings.
The difference in activation status of cells in in vivo and ex vivo tissues may be another reason for the difference in CD8+ T-cell apoptosis in these systems. Activation of lymphoid tissue is one of the hallmarks of HIV disease in vivo. Inappropriate overstimulation of CD8+ T cells in lymph nodes from HIV-infected patients was documented (1). In contrast, evaluation of cytokine production did not reveal any difference between CD8+ T cells isolated from control and ex vivo-infected tissue blocks.
There is a close correlation between apoptosis and the general state of cellular activation (26, 45). Activated CD8+ T cells that infiltrate the lymph nodes of HIV-infected patients were shown to be prone to apoptosis (1). Moreover, CD8+ T cells that were not apoptotic at the time of isolation from HIV-infected individuals enter apoptosis when activated in vitro or simply left in culture (26, 29, 68). The absence of chronic stimulation of CD8+ T cells in ex vivo lymphoid tissue may be the primary reason for the lack of apoptosis in these cells upon HIV infection. This conclusion is in general agreement with the in vivo data that in lymph nodes of HIV-infected individuals apoptosis correlates not with viral burden but rather with the general state of activation (45).
Our results seem to contradict an earlier report that X4 but not R5 HIV-1 isolates induce apoptosis of CD8+ T cells in mixed suspensions of phytohemagglutinin-activated PBMCs and macrophages (32). The discrepancy between the two systems may be explained by the fact that PBMCs have to be artificially stimulated by phytohemagglutinin and IL-2 in order to survive in vitro and to support productive HIV infection. In contrast, human lymphoid tissue ex vivo is self-sufficient and requires exogenous stimulation neither for maintenance nor for productive HIV infection (20). In PBMC cultures, HIV-triggered CD8+ T-cell apoptosis was dependent on the presence of macrophages, with a significant level of apoptosis reached at a 1:4 to 4:1 macrophage/lymphocyte ratio (32). In both ex vivo and in vivo lymphoid tissues, the ratio of macrophages to lymphocytes is much lower. Also, it is conceivable that within the tissue structure, CD8+ T cells are somehow more protected from HIV-induced apoptosis than those in suspension and that the resident lymphocytes are therefore different in this respect from those in the bloodstream. Systematic comparison of the two experimental systems with respect to CD8+ T-cell apoptosis will increase our understanding of the mechanisms of CD8+ T-cell death during HIV infection in vivo.
In conclusion, in human lymphoid tissue ex vivo, HIV-1 induces significant apoptosis in CD4+ T cells but not CD8+ T cells. These results suggest that the mechanisms of HIV-triggered death of CD4+ and CD8+ T cells in vivo may be different. Whereas in lymphoid tissue HIV-1 productive infection is sufficient to trigger apoptosis and consequent depletion of CD4+ T cells, the death of CD8+ T cells requires additional factors. Chronic activation of the immune system may be one of the factors necessary to trigger CD8+ T-cell death, as suggested earlier (1, 15, 26, 34, 45, 48, 61, 62). Human lymphoid tissue ex vivo allows one to study the contribution of productive HIV-1 infection per se to the death and/or dysfunction of CD4+ and CD8+ T cells.
| |
ACKNOWLEDGMENTS |
|---|
The first two authors contributed equally to this work.
This work was supported in part by the NASA/NIH Center for Three Dimensional Tissue Culture.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: NIH, Bldg. 10, Rm. 10D14, Bethesda, MD 20892. Phone: (301) 594-2476. Fax: (301) 480-0857. E-mail: margolis{at}helix.nih.gov.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bofill, M., W. Gombert, N. J. Borthwick, A. N. Akbar, J. E. McLaughlin, C. A. Lee, M. A. Johnson, A. J. Pinching, and G. Janossy. 1995. Presence of CD3+CD8+Bcl-2(low) lymphocytes undergoing apoptosis and activated macrophages in lymph nodes of HIV-1+ patients. Am. J. Pathol. 146:1542-1555[Abstract]. |
| 2. | Bonyhadi, M. L., L. Su, J. Auten, J. M. McCune, and H. Kaneshima. 1995. Development of a human thymic organ culture model for the study of HIV pathogenesis. AIDS Res. Hum. Retroviruses 11:1073-1080[Medline]. |
| 3. | Bouscarat, F., M. Levacher, M. C. Dazza, F. Chau, B. Desforges, M. Muffat-Joly, S. Matheron, P. M. Girard, and M. Sinet. 1999. Prospective study of CD8+ lymphocyte activation in relation to viral load in HIV-infected patients with > or = 400 CD4+ lymphocytes per microliter. AIDS Res. Hum. Retroviruses 15:1419-1425[CrossRef][Medline]. |
| 4. | Bouscarat, F., M. Levacher, R. Landman, M. Muffat-Joly, P. M. Girard, A. G. Saimot, F. Brun-Vezinet, and M. Sinet. 1998. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 12:1267-1273[Medline]. |
| 5. | Bruno, S., and Z. Darzynkiewicz. 1992. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 25:31-40[Medline]. |
| 6. |
Campana, D., and G. Janossy.
1988.
Proliferation of normal and malignant human immature lymphoid cells.
Blood
71:1201-1210 |
| 7. | Casella, C. R., and T. H. Finkel. 1997. Mechanisms of lymphocyte killing by HIV. Curr. Opin. Hematol. 4:24-31[Medline]. |
| 8. |
Cocchi, F.,
A. L. DeVico,
A. Garzino-Demo,
S. K. Arya,
R. C. Gallo, and P. Lusso.
1995.
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.
Science
270:1811-1815 |
| 9. | Cohen, O. J., A. Kinter, and A. S. Fauci. 1997. Host factors in the pathogenesis of HIV disease. Immunol. Rev. 159:31-48[CrossRef][Medline]. |
| 10. |
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628 |
| 11. | Fauci, A. S. 1996. Host factors and the pathogenesis of HIV-induced disease. Nature 384:529-534[CrossRef][Medline]. |
| 12. |
Fauci, A. S.
1993.
Multifactorial nature of human immunodeficiency virus disease: implications for therapy.
Science
262:1011-1018 |
| 13. | Fauci, A. S. 1996. Resistance to HIV-1 infection: it's in the genes. Nat. Med. 2:966-967[CrossRef][Medline]. |
| 14. |
Fauci, A. S.,
G. Pantaleo,
S. Stanley, and D. Weissman.
1996.
Immunopathogenic mechanisms of HIV infection.
Ann. Intern. Med.
124:654-663 |
| 15. | Feng, Y. R., R. J. Biggar, D. Gee, D. Norwood, S. L. Zeichner, and D. S. Dimitrov. 1999. Long-term telomere dynamics: modest increase of cell turnover in HIV-infected individuals followed for up to 14 years. Pathobiology 67:34-38[CrossRef][Medline]. |
| 16. | Finkel, T. H., G. Tudor-Williams, N. K. Banda, M. F. Cotton, T. Curiel, C. Monks, T. W. Baba, R. M. Ruprecht, and A. Kupfer. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1:129-134[CrossRef][Medline]. |
| 17. |
Fiorentino, S.,
M. Dalod,
D. Olive,
J. G. Guillet, and E. Gomard.
1996.
Predominant involvement of CD8+ CD28 lymphocytes in human immunodeficiency virus-specific cytotoxic activity.
J. Virol.
70:2022-2026[Abstract].
|
| 18. | Freitas, A. A., and B. B. Rocha. 1993. Lymphocyte lifespans: homeostasis, selection and competition. Immunol. Today 14:25-29[CrossRef][Medline]. |
| 19. | Gerdes, J., H. Lemke, H. Baisch, H. H. Wacker, U. Schwab, and H. Stein. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1710-1715[Abstract]. |
| 20. | Glushakova, S., B. Baibakov, L. B. Margolis, and J. Zimmerberg. 1995. Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat. Med. 1:1320-1322[CrossRef][Medline]. |
| 21. | Glushakova, S., B. Baibakov, J. Zimmerberg, and L. Margolis. 1997. Experimental HIV infection of human lymphoid tissue: correlation of CD4+ T cell depletion and virus syncytium-inducing/non-syncytium-inducing phenotype in histoculture inoculated with laboratory strains and patient isolates of HIV type 1. AIDS Res. Hum. Retroviruses 13:461-471[Medline]. |
| 22. | Glushakova, S., J. C. Grivel, W. Fitzgerald, A. Sylwester, J. Zimmerberg, and L. B. Margolis. 1998. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat. Med. 4:346-349[CrossRef][Medline]. |
| 23. |
Glushakova, S.,
J. C. Grivel,
K. Suryanarayana,
P. Meylan,
J. D. Lifson,
R. Desrosiers, and L. Margolis.
1999.
Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo.
J. Virol.
73:3968-3974 |
| 24. | Glushakova, S., Y. Yi, J. C. Grivel, A. Singh, D. Schols, E. De Clercq, R. G. Collman, and L. Margolis. 1999. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J. Clin. Investig. 104:R7-R11. |
| 25. | Gougeon, M. L., A. G. Laurent-Crawford, A. G. Hovanessian, and L. Montagnier. 1993. Direct and indirect mechanisms mediating apoptosis during HIV infection: contribution to in vivo CD4 T cell depletion. Semin. Immunol. 5:187-194[CrossRef][Medline]. |
| 26. | Gougeon, M. L., H. Lecoeur, A. Dulioust, M. G. Enouf, M. Crouvoiser, C. Goujard, T. Debord, and L. Montagnier. 1996. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156:3509-3520[Abstract]. |
| 27. | Gougeon, M. L., E. Ledru, H. Lecoeur, and S. Garcia. 1998. T cell apoptosis in HIV infection: mechanisms and relevance for AIDS pathogenesis. Results Probl. Cell Differ. 24:233-248[Medline]. |
| 28. | Grivel, J. C., and L. B. Margolis. 1999. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nat. Med. 5:344-346[CrossRef][Medline]. |
| 29. |
Groux, H.,
G. Torpier,
D. Monte,
Y. Mouton,
A. Capron, and J. C. Ameisen.
1992.
Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals.
J. Exp. Med.
175:331-340 |
| 30. |
Hay, C. M.,
D. J. Ruhl,
N. O. Basgoz,
C. C. Wilson,
J. M. Billingsley,
M. P. DePasquale,
R. T. D'Aquila,
S. M. Wolinsky,
J. M. Crawford,
D. C. Montefiori, and B. D. Walker.
1999.
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection.
J. Virol.
73:5509-5519 |
| 31. | Hellerstein, M., M. B. Hanley, D. Cesar, S. Siler, C. Papageorgopoulos, E. Wieder, D. Schmidt, R. Hoh, R. Neese, D. Macallan, S. Deeks, and J. M. McCune. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5:83-89[CrossRef][Medline]. |
| 32. | Herbein, G., U. Mahlknecht, F. Batliwalla, P. Gregersen, T. Pappas, J. Butler, W. A. O'Brien, and E. Verdin. 1998. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395:189-194[CrossRef][Medline]. |
| 33. | Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126[CrossRef][Medline]. |
| 34. | Ho, H. N., L. E. Hultin, R. T. Mitsuyasu, J. L. Matud, M. A. Hausner, D. Bockstoce, C. C. Chou, S. O'Rourke, J. M. Taylor, and J. V. Giorgi. 1993. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J. Immunol. 150:3070-3079[Abstract]. |
| 35. |
Klein, M. R.,
C. A. van Baalen,
A. M. Holwerda,
S. R. Kerkhof Garde,
R. J. Bende,
I. P. Keet,
J. K. Eeftinck-Schattenkerk,
A. D. Osterhaus,
H. Schuitemaker, and F. Miedema.
1995.
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.
J. Exp. Med.
181:1365-1372 |
| 36. | Koester, S. K., P. Roth, W. R. Mikulka, S. F. Schlossman, C. Zhang, and W. E. Bolton. 1997. Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody APO2.7. Cytometry 29:306-312[CrossRef][Medline]. |
| 37. |
Koot, M.,
I. P. M. Keet,
A. H. V. Vos,
R. E. Y. DeGoede,
M. T. L. Roos,
R. A. Coutinho,
F. Miedema,
P. T. A. Schellekens, and M. Tersmette.
1993.
Prognostic value of HIV-1 syncytium-inducing phenotype for rates of CD4+ cell depletion and progression to AIDS.
Ann. Intern. Med.
118:681-688 |
| 38. | Levy, J. A., C. E. Mackewicz, and E. Barker. 1996. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol. Today 17:217-224[CrossRef][Medline]. |
| 39. | Margolick, J. B., A. Munoz, A. D. Donnenberg, L. P. Park, N. Galai, J. V. Giorgi, M. R. O'Gorman, and J. Ferbas. 1995. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat. Med. 1:674-680. |
| 40. | Margolis, L. B., W. Fitzgerald, S. Glushakova, S. Hatfill, N. Amichay, B. Baibakov, and J. Zimmerberg. 1997. Lymphocyte trafficking and HIV infection of human lymphoid tissue in a rotating wall vessel bioreactor. AIDS Res. Hum. Retroviruses 13:1411-1420[Medline]. |
| 41. | Metivier, D., B. Dallaporta, N. Zamzami, N. Larochette, S. A. Susin, I. Marzo, and G. Kroemer. 1998. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol. Lett. 61:157-163[CrossRef][Medline]. |
| 42. |
Meyaard, L.,
S. A. Otto,
R. R. Jonker,
M. J. Mijnster,
R. P. Keet, and F. Miedema.
1992.
Programmed death of T cells in HIV-1 infection.
Science
257:217-219 |
| 43. | Meyaard, L., S. A. Otto, I. P. Keet, M. T. Roos, and F. Miedema. 1994. Programmed death of T cells in human immunodeficiency virus infection. No correlation with progression to disease. J. Clin. Investig. 93:982-988. |
| 44. |
Mohri, H.,
S. Bonhoeffer,
S. Monard,
A. S. Perelson, and D. D. Ho.
1998.
Rapid turnover of T lymphocytes in SIV-infected rhesus macaques.
Science
279:1223-1227 |
| 45. | Muro-Cacho, C. A., G. Pantaleo, and A. S. Fauci. 1995. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J. Immunol. 154:5555-5566[Abstract]. |
| 46. |
Palmer, L. D.,
N. Weng,
B. L. Levine,
C. H. June,
H. C. Lane, and R. J. Hodes.
1997.
Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins.
J. Exp. Med.
185:1381-1386 |
| 47. | Pantaleo, G., and A. S. Fauci. 1996. Immunopathogenesis of HIV infection. Annu. Rev. Microbiol. 50:825-854[CrossRef][Medline]. |
| 48. | Pantaleo, G., and A. S. Fauci. 1995. New concepts in the immunopathogenesis of HIV infection. Annu. Rev. Immunol. 13:487-512[CrossRef][Medline]. |
| 49. |
Penn, M. L.,
J. C. Grivel,
B. Schramm,
M. A. Goldsmith, and L. Margolis.
1999.
CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.
Proc. Natl. Acad. Sci. USA
96:663-668 |
| 50. | Rosenzweig, M., E. M. Bunting, R. L. Damico, D. P. Clark, and G. N. Gaulton. 1994. Human neonatal thymic organ culture: an ex vivo model of thymocyte ontogeny and HIV-1 infection. Pathobiology 62:245-251[Medline]. |
| 51. |
Rosenzweig, M.,
M. A. DeMaria,
D. M. Harper,
S. Friedrich,
R. K. Jain, and R. P. Johnson.
1998.
Increased rates of CD4(+) and CD8(+) T lymphocyte turnover in simian immunodeficiency virus-infected macaques.
Proc. Natl. Acad. Sci. USA
95:6388-6393 |
| 52. | Rosok, B. I., J. E. Brinchmann, G. Stent, R. Bjerknes, P. Voltersvik, J. Olofsson, and B. Asjo. 1998. Correlates of apoptosis of CD4+ and CD8+ T cells in tonsillar tissue in HIV type 1 infection. AIDS Res. Hum. Retroviruses 14:1635-1643[Medline]. |
| 53. |
Sachsenberg, N.,
A. S. Perelson,
S. Yerly,
G. A. Schockmel,
D. Leduc,
B. Hirschel, and L. Perrin.
1998.
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen.
J. Exp. Med.
187:1295-1303 |
| 54. | Scarlatti, G., E. Tresoldi, A. Bjorndal, R. Fredriksson, C. Colognesi, H. K. Deng, M. S. Malnati, A. Plebani, A. G. Siccardi, D. R. Littman, E. M. Fenyo, and P. Lusso. 1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3:1259-1265[CrossRef][Medline]. |
| 55. |
Schuitemaker, H.,
M. Koot,
N. A. Kootstra,
M. W. Dercksen,
R. E. de Goede,
R. P. van Steenwijk,
J. M. Lange,
J. K. Schattenkerk,
F. Miedema, and M. Tersmette.
1992.
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
J. Virol.
66:1354-1360 |
| 56. | Sodroski, J., W. Haseltine, and M. Kowalski. 1991. Role of the human immunodeficiency virus type I envelope glycoprotein in cytopathic effect. Adv. Exp. Med. Biol. 300:193-199[Medline]. |
| 57. |
Stewart, S. A.,
B. Poon,
J. Y. Song, and I. S. Chen.
2000.
Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation.
J. Virol.
74:3105-3111 |
| 58. |
Strack, P. R.,
M. W. Frey,
C. J. Rizzo,
B. Cordova,
H. J. George,
R. Meade,
S. P. Ho,
J. Corman,
R. Tritch, and B. D. Korant.
1996.
Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2.
Proc. Natl. Acad. Sci. USA
93:9571-9576 |
| 59. |
Sylwester, A. W.,
J. C. Grivel,
W. Fitzgerald,
J. L. Rossio,
J. D. Lifson, and L. B. Margolis.
1998.
CD4+ T-lymphocyte depletion in human lymphoid tissue ex vivo is not induced by noninfectious human immunodeficiency virus type 1 virions.
J. Virol.
72:9345-9347 |
| 60. | Tersmette, M., J. M. Lange, R. E. de Goede, F. de Wolf, J. K. Eeftink-Schattenkerk, P. T. Schellekens, R. A. Coutinho, J. G. Huisman, J. Goudsmit, and F. Miedema. 1989. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet i:983-985. |
| 61. | Tough, D. F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272:1947-1950[Abstract]. |
| 62. | Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345-8[CrossRef][Medline]. |
| 63. | Walker, B. D., E. S. Rosenberg, C. M. Hay, N. Basgoz, and O. O. Yang. 1998. Immune control of HIV-1 replication. Adv. Exp. Med. Biol. 452:159-167[Medline]. |
| 64. | Westendorp, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K. M. Debatin, and P. H. Krammer. 1995. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497-500[CrossRef][Medline]. |
| 65. |
Wolthers, K. C.,
G. Bea,
A. Wisman,
S. A. Otto,
A. M. de Roda Husman,
N. Schaft,
F. de Wolf,
J. Goudsmit,
R. A. Coutinho,
A. G. van der Zee,
L. Meyaard, and F. Miedema.
1996.
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover.
Science
274:1543-1547 |
| 66. | Wolthers, K. C., H. Schuitemaker, and F. Miedema. 1998. Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. Immunol. Today 19:44-48[CrossRef][Medline]. |
| 67. |
Xu, X. N.,
B. Laffert,
G. R. Screaton,
M. Kraft,
D. Wolf,
W. Kolanus,
J. Mongkolsapay,
A. J. McMichael, and A. S. Baur.
1999.
Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain.
J. Exp. Med.
189:1489-1496 |
| 68. | Yang, Y., and J. Ashwell. Exploiting the apoptotic process for management of HIV: are we there yet? Apoptosis, in press. |
| 69. |
Zhang, Z.,
T. Schuler,
M. Zupancic,
S. Wietgrefe,
K. A. Staskus,
K. A. Reimann,
T. A. Reinhart,
M. Rogan,
W. Cavert,
C. J. Miller,
R. S. Veazey,
D. Notermans,
S. Little,
S. A. Danner,
D. D. Richman,
D. Havlir,
J. Wong,
H. L. Jordan,
T. W. Schacker,
P. Racz,
K. Tenner-Racz,
N. L. Letvin,
S. Wolinsky, and A. T. Haase.
1999.
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.
Science
286:1353-1357 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»